These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29590345)

  • 1. Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease.
    Papamichael K; Vajravelu RK; Vaughn BP; Osterman MT; Cheifetz AS
    J Crohns Colitis; 2018 Jun; 12(7):804-810. PubMed ID: 29590345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
    Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
    Borren NZ; Paulides E; Frinack JL; Olson RN; Willrich MAV; van der Woude CJ; Ananthakrishnan AN
    Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
    Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
    Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial.
    Bossuyt P; Pouillon L; Claeys S; D'Haens S; Hoefkens E; Strubbe B; Marichal D; Peeters H
    J Crohns Colitis; 2022 Feb; 16(2):199-206. PubMed ID: 34297099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.
    Lega S; Phan BL; Rosenthal CJ; Gordon J; Haddad N; Pittman N; Benkov KJ; Dubinsky MC
    Inflamm Bowel Dis; 2019 Jan; 25(1):134-141. PubMed ID: 29868777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn's disease.
    Zhang Y; Jiang W; Xu C; Tian J; Chen J; Zhang H
    Scand J Gastroenterol; 2024 Mar; 59(3):269-279. PubMed ID: 37991266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings.
    Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Williams AJ; Ng W; Connor S
    Intern Med J; 2021 May; 51(5):739-745. PubMed ID: 31589357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
    Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
    J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
    Taxonera C; Barreiro-de Acosta M; Calvo M; Saro C; Bastida G; Martín-Arranz MD; Gisbert JP; García-Sánchez V; Marín-Jiménez I; Bermejo F; Chaparro M; Ponferrada Á; Martínez-Montiel MP; Pajares R; de Gracia C; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
    Dig Dis Sci; 2015 Oct; 60(10):3075-84. PubMed ID: 26044830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.
    Ljung T; Karlén P; Schmidt D; Hellström PM; Lapidus A; Janczewska I; Sjöqvist U; Löfberg R
    Gut; 2004 Jun; 53(6):849-53. PubMed ID: 15138212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery.
    Barnes EL; Goldin A; Winter RW; Collins E; Cao B; Carrellas M; Crowell AM; Korzenik JR
    Dig Dis Sci; 2016 Nov; 61(11):3261-3269. PubMed ID: 27639871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab.
    Porth R; Deyhim T; Zullow S; Rabinowitz LG; Grossberg LB; Roblin X; Paul S; Cheifetz AS; Papamichael K
    Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 38953651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    J Crohns Colitis; 2018 Nov; 12(11):1316-1325. PubMed ID: 30239644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab.
    Barberio B; D'Incà R; Facchin S; Dalla Gasperina M; Fohom Tagne CA; Cardin R; Ghisa M; Lorenzon G; Marinelli C; Savarino EV; Zingone F
    Inflamm Bowel Dis; 2020 Apr; 26(5):756-763. PubMed ID: 31504536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD.
    Falaiye TO; Mitchell KR; Lu Z; Saville BR; Horst SN; Moulton DE; Schwartz DA; Wilson KT; Rosen MJ
    J Pediatr Gastroenterol Nutr; 2014 Feb; 58(2):213-9. PubMed ID: 24048170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.
    Papamichael K; Vajravelu RK; Osterman MT; Cheifetz AS
    Dig Dis Sci; 2018 Mar; 63(3):761-767. PubMed ID: 29340807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease.
    Sánchez-Hernández JG; Rebollo N; Martin-Suarez A; Calvo MV; Muñoz F
    Br J Clin Pharmacol; 2020 Jun; 86(6):1165-1175. PubMed ID: 32022291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort.
    Negoescu DM; Enns EA; Swanhorst B; Baumgartner B; Campbell JP; Osterman MT; Papamichael K; Cheifetz AS; Vaughn BP
    Inflamm Bowel Dis; 2020 Jan; 26(1):103-111. PubMed ID: 31184366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.